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Abstract
Background:  Oncogene signaling is known to deregulate cell proliferation resulting in
uncontrolled growth and cellular transformation. Gene amplification and/or somatic mutations of
the HER2/Neu (ErbB2) proto-oncogene occur in approximately 20% of breast cancers. A
therapeutic strategy that has been used to block HER2 function is the small molecule tyrosine
kinase inhibitor lapatinib. Using human mammary epithelial cells that overexpress HER2, we
determined the anti-proliferative effect of lapatinib through measuring the total cell number and
analyzing the cell cycle distribution. A mathematical model was used to interpret the experimental
data.
Results: The model suggests that lapatinib acts as expected by slowing the transition through G1
phase. However, the experimental data indicated a previously unreported late cytotoxic effect,
which was incorporated into the model. Both effects depend on the dosage of the drug, which
shows saturation kinetics.
Conclusion: The model separates quantitatively the cytostatic and cytotoxic effects of lapatinib
and may have implications for preclinical studies with other anti-oncogene therapies.
Background
Molecule-targeted anti-cancer drugs have been developed
as a result of our understanding of tumor cell and molec-
ular biology. Compared to "traditional" cancer therapies,
targeted drugs such as the tyrosine kinase inhibitors
(TKIs) have higher specificity and relatively lower toxicity
in selected patients with corresponding oncogene expres-
sion. Members of the type 1 receptor tyrosine kinase
(RTK) family, which includes the epidermal growth factor
receptor (EGFR), HER2 (ErbB2), HER3 and HER4 play a
crucial role in growth and differentiation of both normal
and malignant mammary epithelial cells [1,2]. Binding of
receptor-specific ligands to the ectodomain of EGFR,
HER3 and HER4 results in the formation of receptor dim-
ers and hetero-oligomers to which HER2 is recruited as
the preferred heterodimerization partner [3]. HER2 gene
amplification has been reported in approximately 20% of
breast cancers, where it is associated with poor patient
outcome [4]. Studies with HER2-overexpressing breast
cancer cell lines and human tumors have shown constitu-
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tive phosphorylation of HER2 [5,6]. Overexpression of
HER2 is associated with transformation of mammary epi-
thelial cells [7,8] as well as shorter survival in patients
with breast carcinoma [4,9]. These facts make HER2 a
rational therapeutic target in human breast cancer. One
therapeutic approach against HER2-overexpressing breast
cancers is the generation of trastuzumab, a humanized
IgG1 that binds to residues 529–626 in domain IV of the
HER2 ectodomain [2,10]. However, many patients with
HER2-overexpressing advanced disease do not respond
clinically to trastuzumab and many that initially respond
eventually relapse with antibody-resistant disease. Lapat-
inib (GW572016, GlaxoSmithKline) is a selective reversi-
ble inhibitor of both EGFR and HER2 tyrosine kinases.
Lapatinib mimics ATP and binds to the ATP site in the
tyrosine kinase domain of HER2, resulting in blockade of
the receptor's catalytic activity [11].
Preclinical data have shown that tumor cells overexpress-
ing EGFR or HER2 are growth inhibited by lapatinib both
in vitro and in vivo [12-14]. Lapatinib inhibits the activa-
tion of cell proliferation effectors, Erk1/2 (also known as
mitogen-activated protein kinase, or MAPK) and AKT,
which are downstream of EGFR and HER2 [11,15]. In
another study in which over 30 breast cancer cell lines
were tested for their responses to lapatinib, concentration-
dependent antiproliferative effects of lapatinib were seen
in all cells but varied significantly between individual cell
lines [13]. Response to lapatinib is significantly correlated
with HER2 expression and its ability to inhibit the phos-
phorylation of HER2 and downstream effectors. In phase
II clinical trials, treatment with lapatinib resulted in objec-
tive tumor responses in 28% of patients with HER2-posi-
tive advanced breast cancer [12]. Modeling the
antiproliferative effects of this oncogene inhibitor using
mathematical tools will lead to novel insights into the
functioning features and mechanisms of the inhibitor.
The model may also provide constructive clinical implica-
tions, such as the predictive effects of the inhibitor in first-
line therapy in combination with chemotherapy.
In this study we used MCF10A human mammary epithe-
lial cells engineered to overexpress HER2 in order to deter-
mine the anti-tumor effects of lapatinib. Compared to
control MCF10A cells that do not overexpress HER2,
MCF10A/HER2 cells exhibit a gain-of-function phenotype
including increased proliferation and filling of the lumen
when grown in three dimensions, as a result of oncogene
overexpression [16]. Lapatinib inhibits the phosphoryla-
tion and function of HER2 in these cells and suppresses
growth [16]. At the molecular level the functional mecha-
nisms of HER2 inhibitors are evaluated by the activities of
downstream signaling networks, which are often deter-
mined by immunoblots. However, signaling pathways
such as the PI3K/Akt and the MEK/Erk pathways can con-
verge at various levels of the signaling cascades, making it
difficult to separate a combined effect on cell growth and
survival. Quantitative models can separate the strengths of
drug action on individual phases of the cell cycle. Previous
molecular biological studies have shown that HER2 is
associated with increases of both G1-S-specific cyclins
(cyclins D and E) and G2-M-specific cyclin (cyclin A)
[17,18], which are crucial for G1-S and G2-M progression,
respectively. Our objective in this study is to use quantita-
tive models to determine if HER2 inhibitors abolish the
function on both phase transitions and how this contrib-
utes to cell cycle blockage.
Mathematical modeling has been applied extensively to
study the growth kinetics of tumors, with and without
treatment; see [19-26] and the references therein. These
authors have focused on phenomena such as decelerated
growth, quiescence, homeostasis and chemotherapy
scheduling.
It has been recognized that, apart from killing cells out-
right, anticancer drugs can also act by delaying the pro-
gression through the cell cycle. Moreover, this blocking
effect can be phase specific [27]. Transition through one
phase of the cell cycle may be delayed while transition
through another phase is unaffected. Mathematical mod-
eling here provides the tool to test possible alternative sce-
narios against each other and to gain new insight. In a
series of papers, Ubezio and collaborators used a mathe-
matical modeling approach to investigate phase-specific
cytotoxic and cytostatic effects of drugs such as cisplatin,
melphalan and topotecan in vitro [26-29]. A continuous
model has been used by Agur and coworkers [22] to pre-
dict the effect of periodic treatments with cycle-specific
cytotoxic drugs.
Our mathematical model consists of populations of pro-
liferating and nonproliferating cells with individual cells
distinguished by cell cycle position and is described in
detail below. Numerical simulations of the model give
good agreement with the experimental data. We find that
the experimental data are consistent with a theory in
which lapatinib preferentially affects cells growing in
monolayer culture in G1-phase in a dose-specific manner.
As the dose of lapatinib is increased, however, our study
indicates that other phases of the cell cycle are affected as
well. Moreover, we see a gradual onset of the cytostatic
effect as opposed to a sudden onset. We observe a simple
functional relationship between the strength of the cyto-
static effect and the drug concentration (see equation (13)
for details). Finally, our study indicates that a cytotoxic
effect is present after longer periods of exposure to the
drug.Theoretical Biology and Medical Modelling 2007, 4:14 http://www.tbiomed.com/content/4/1/14
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Results
In the control scenario (without treatment) the cell counts
showed an initial exponential increase of the population
and then a leveling off (see Figure 1A). To explain this lev-
eling off, the nonproliferating cell class was incorporated
into the model. Nonlinear models with nonproliferating
subpopulations have been used extensively to explain
Gompertzian growth kinetics of tumors [20,21]. Prolifer-
ating cells enter the nonproliferating class irreversibly at a
rate dependent on their maturity and the total population
count of both proliferating and nonproliferating cells.
This nonlinearity in the model accounts for the conflu-
ence observed in the control study on day 6. Staining of
cells with the marker for proliferation Ki-67 showed a dra-
matic decrease of the proliferating fraction from day 4 to
day 6 (see Figure 2B), well borne out by the numerical
simulation. In the model, nonproliferating cells arrested
their maturity value at the moment of transition from pro-
liferation (see equations (2)–(3)). No mortality of cells
was assumed in the model for the control, since no
decrease in cell numbers was observed. In addition, stain-
ing for the marker of apoptosis Caspase-3 was negative for
the control (data not shown). The flow cytometric data
from the control scenario are shown in Figure 1B. Owing
to uncertainty in the experimental measurements, there
were some discrepancies in the fit, particularly during
days 1 – 3.
The model for the control case was used as a reference for
the treatment cases, with two separate effects of the drug
added. The first was the cytostatic effect, which slowed
maturation velocity. Our numerical simulations indicate
that lapatinib preferentially blocks cells in G1-phase. At
higher dose (2 μM) the model also incorporates blocking
effects in G2/M phase. We find that the strength of the
cytostatic effect saturates at higher doses (see Table 1 and
Figure 3A). The second effect of the drug was a cytotoxic
action. This was incorporated into the model to explain
the decrease in cell counts from day 5 to day 6, which was
not present in the control (Figure 4). In the model it was
assumed that this cytotoxic action only set in after 5 days.
This is supported by experimental observations, as stain-
ing for the marker of apoptosis Caspase-3 was negative
before day 5 (Figure 5). The model simulations agreed
substantially with the experimental data, both in the total
population counts and the flow cytometric data (Figure
1C, D).
Discussion and conclusion
The mathematical model provided a means to separate
the cytostatic and cytotoxic action of the drug in the exper-
iments. We summarize our findings as follows.
Cell cycle specificity of cytostatic effects
The strength of the cytostatic effects depends on the drug
dosage; the drug showed saturation kinetics (see the last
section and Figure 3A for details). At low concentrations
(0.1 – 1 μM) only cells in G1-phase are delayed. At higher
concentrations (2 μM) we hypothesize, on the basis of our
model simulations, that cells in G2-phase are delayed as
well and may be prevented from entering mitosis. It was
not necessary to introduce a cytostatic effect for cells in S-
phase. We therefore suggest that cells in S-phase remain
unaffected at all concentrations.
Dynamic behavior
Our numerical simulations indicate a buildup phase for
the drug action that stretches over several days. Initially
we assumed a sudden onset of the cytostatic action after a
certain time. The simulations showed pronounced oscilla-
tions in the fractions of cells in each phase that were not
observed in the data (simulations not shown). We then
assumed a gradual increase (with respect to time) of the
cytostatic effects. As the cycle time of an average cell is less
than one day, we conjecture that the initial effects of the
drugs alters a cell's protein contents but still allows divi-
sion. Only after several generations is the progression of
the cells through the respective cell cycle phases fully
retarded. The same holds for the loss of cells. This can be
explained by the functional mechanism of the drug and
the nature of cell mitosis. Oncogene inhibitors such as
lapatinib affect the activities of oncogene downstream
effectors, which usually include regulatory proteins cru-
cial for proliferation and survival. As cytoplasmic division
occurs during mitosis, the inhibitory effect of lapatinib on
these crucial effectors can be "inherited" as protein con-
centration in the cytosol, where the drug effect can further
accumulate. Once the concentrations of these crucial pro-
teins exceed certain thresholds, physiological effects such
as growth arrest and apoptosis will be induced in the
descendant cells. The conclusions that the length of lapat-
inib treatment is crucial for the overall drug effects, and
that it takes several cell generations for the drug to show a
clear cellular effect, especially at a lower concentration,
may have potential clinical implications.
The cytotoxic effect
A model with cytostatic action alone cannot lead to a
decrease in total cell number, which made it necessary to
introduce a cytotoxic effect. To explain the additional
mortality of cells after 120 hours, we propose that cells in
which progression through the cell cycle has been
retarded for too long become prone to apoptosis in the
presence of lapatinib. We conjecture that the strength of
the cytotoxic effect also saturates at higher doses, as is sug-
gested by Figure 3B.Theoretical Biology and Medical Modelling 2007, 4:14 http://www.tbiomed.com/content/4/1/14
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While it is difficult to extrapolate conclusions from our in
vitro study to the in vivo situation, the following sugges-
tions are plausible. Lapatinib acts chiefly through slowing
the progression of proliferating cells in monolayer cul-
ture. Furthermore, it is advisable to combine lapatinib
with cytotoxic therapeutic agents that kill not only prolif-
erating cells but also quiescent cells, such as some alkylat-
ing agents. These drugs may complement the antitumor
effect of lapatinib and therefore serve as good candidates
to be tested in combined treatment in the future.
We have shown that a mathematical model based on pop-
ulation dynamics can be applied to interpret the cytostatic
and cytotoxic effects of lapatinib. Earlier mathematical
Total cell counts A and flow cytometric data B for untreated cells Figure 1
Total cell counts A and flow cytometric data B for untreated cells. Discrete symbols designate averages of three independent 
realizations of the experiment while curves are the predictions of our model. In panel A the total number of cells is shown in 
blue while the number of nonproliferating cells is shown in red. This prediction agrees well with the measurements in Figure 2 
B. In panel B the fraction of cells in each phase is shown. In this and in the subsequent figures individual symbols mark experi-
mental measurements while the curves are the corresponding simulations. Total cell counts C and flow cytometric data D for 
cells treated with 1 μM lapatinib. These graphs are representative of all drug treatment cases.
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models [27] used a discrete partition of the cell cycle into
age compartments and also a discrete time scale. We find
that continuum models are advantageous from the view-
point of parametrization and computability. In particular,
the number of free parameters in our model is signifi-
cantly smaller than in previously proposed models and
each has a straightforward biological interpretation. Both
the cytostatic and cytotoxic effects of lapatinib are cur-
rently being investigated in various other HER2-overex-
pressing breast cancer cell lines. Our model can certainly
be applied to other oncogene inhibitors that have cyto-
static effects on cells during a specific phase of the cell
cycle.
Materials and methods
MCF10A/HER2 cells were generated and grown as
described [30]. Lapatinib was kindly provided by Tona
Gilmer (GlaxoSmithKline, Research Triangle Park, NC).
A Phase contrast images of untreated cells on different days Figure 2
A Phase contrast images of untreated cells on different days. B Staining of untreated cells for marker of proliferation Ki-67 
(green) on days 4 to 6. Blue: DAPI staining showing total nuclei. The simulations predict 100%, 40% and 4% proliferating frac-
tion on days 4, 5 and 6, respectively (see Figure 1 A).
a)
b)Theoretical Biology and Medical Modelling 2007, 4:14 http://www.tbiomed.com/content/4/1/14
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Equal numbers of cells (3·104/well) were seeded on 6-
well plates for growth assay and cell cycle analysis over a
time course of 6 days. At 4 h post seeding when > 98% of
cells were attached to the plates, the cells were either har-
vested by trypsinization as day 0 samples, or treated by
different doses (0.1, 0.5, 1 and 2 μM) of lapatinib, which
was added and left in the medium throughout. Media
containing fresh drug were replenished every 2 days. Cells
were harvested by trypsinization every 8 h after adding
drug for the initial 3 days and every 24 h for days 4–6. One
tenth of the cells collected (100 μl out of 1 ml) were sub-
jected to total cell number counting using a Coulter coun-
ter. The rest of the cells (900 μl out of 1 ml) were subjected
to cell cycle analysis. For flow cytometric analysis of cell
cycle distribution, cells were fixed in 70% ethanol for 24
h at – 20°C, and rehydrated in cold phosphate buffered
saline (PBS) for 30 min on ice. Redydrated cells were sub-
sequently labeled with 50 μg/ml  propidium iodide
(Sigma, St. Louis, MO) containing 125 units/ml protease-
free RNase (Calbiochem, San Diego, CA) in the dark for
30 min at room temperature and filtered through a 95 μm
pore size nylon mesh (Small Parts, Miami Lakes, FL). A
total of 10,000 stained nuclei was analyzed in a FACS/Cal-
ibur Flow Cytometer (BD Biosciences, Franklin Lakes,
NJ). All treatments were done in triplicate.
Indirect immunofluorescence assays (IFA) were per-
formed as described previously [16] to detect markers for
proliferation and apoptosis. Fluorescent images were cap-
tured using a Zeiss inverted LSM510 confocal microscopy
system. Primary antibodies include Ki-67 (Calbiochem)
and cleaved caspase-3 (Cell Signaling, Danvers, MA). The
Table 1: Numerical values of the parameters that are fixed throughout all scenarios
parameter numerical value remarks
7 h G1/S-boundary in absence of drugs
aS 11 h S/G2-boundary in absence of drugs
am 15 h minimal age for division
aM 30 h maximal cell age
σ 2 standard deviation of intermitotic times
c 0.22 nonproliferation constant
M0 6·105 cells crowding threshold for nonproliferation
μ(a) {1, 0.25, 0.6} see Figure 6 B
aG1
The values  (d) A and ε0(d) B as functions of dose show saturation (see equations (13)-(14) and Table 2) Figure 3
The values   (d) A and ε0(d) B as functions of dose show saturation (see equations (13)-(14) and Table 2)
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fluorescent antibodies were Oregon Green-α-mouse IgG
and Texas Red-α-rabbit IgG (Molecular Probes, Carlsbad,
CA).
The mathematical model was designed to quantify the
cytostatic and cytotoxic effects of the drug on the basis of
the population dynamics observed in the experiments.
The model consists of a system of differential equations
describing these dynamics over the 6 day time course (see
the last section for a detailed description). Cells are classi-
fied as proliferating or nonproliferating. In the model,
proliferating cells are tracked according to position in the
cell cycle by assigning to each cell a variable called matu-
rity. Maturity in the control scenario (0 μM lapatinib) cor-
responds to cell age (i.e., time that has passed since the last
mitosis). The maturity values in the control delimiting the
phases of the cell cycle are set at 0 – 7 h (G1), 7 – 11 h (S),
and 11 – 30 h (G2/M) (see Figure 6B and the last section
for further explanation). The model takes into account the
variability of intermitotic times with mean age of division
approximately 19 h in the control (see Figure 6A). The
mathematical model was programmed using MATLAB
(version 7.1, The MathWorks, Inc., Natick, MA). The
codes are available upon request from the corresponding
author. A standard upwind scheme is used for the numer-
ical solution of the partial differential equations [31].
The mathematical model
Let t ≥ 0 denote the time since the beginning of the exper-
iment and a ∈ [0, aM ] denote the maturity of a cell. This
Combined cell counts and simulations for the control and various drug concentrations Figure 4
Combined cell counts and simulations for the control and various drug concentrations. The goodness-of-fit is comparable 
across the different drug doses.
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maturity variable can be thought of as the position of a
cell in its cell cycle. We wish to emphasize that in the
absence of cytostatic effects of drugs, maturity coincides
with chronological age, the time since cell division. In
experimental terms, maturity is measured by differential
DNA-content. See the discussion in [26] for further infor-
mation.
Let p(a, t) and n(a, t) denote the densities of proliferating
and nonproliferating cells, respectively, of maturity a at
time t. The total number of cells at time t is obtained by
integrating both densities over the age space
We state our model equations, which balance the biolog-
ical processes occurring in time
p(a, 0) = p0(a),
n(a, 0) = n0(a).
The left hand side of equation (2) describes the aging
process for proliferating cells. On the right hand side of
the same equation we find that cells of maturity a are lost
due to three independent processes. Firstly, cells undergo
mitosis, at a rate β depending on a. Such a cell shows up
as two proliferating cells of maturity 0, hence the bound-
ary condition (4). Secondly, proliferating cells are also
lost due to a transition into the nonproliferating class. In
contrast to proliferating cells, the nonproliferating cells do
not mature and do not give rise to new cells. The rate at
which the transition between the two classes occurs,  ,
Mt pat nat a
aM () ((,) (,) ) . =+ ∫ d
0
∂
∂
+
∂
∂
−= − + +
t
pat
a
at pat a aMt t pa (,) ( ( (,) )(,) ) ( () (, () ) () )( 1 δβ μ ε  , ,) , t
∂
∂
=−
t
nat aMt pat tnat (,) (, () )(,) ()(,) ,  με
( (,) )(,) ()(,) , 10 0 2
0 −= ∫ δβ tp t a p a ta
aM d
 μ
On days 4–6, cells treated with 1 and 2 μM lapatinib respectively are stained for cleaved Caspase-3 (red), a marker of apopto- sis Figure 5
On days 4–6, cells treated with 1 and 2 μM lapatinib respectively are stained for cleaved Caspase-3 (red), a marker of apopto-
sis. Blue: DAPI staining showing total nuclei.Theoretical Biology and Medical Modelling 2007, 4:14 http://www.tbiomed.com/content/4/1/14
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depends on the maturity a of the respective cell as well as
on the total number of cells M. We set
The function μ(a) is depicted in Figure 6B and its param-
eters are given in Table 1. The particular choice of a piece-
wise constant function is a result of the experimental
observations for the control scenario (Figure 1B). Indeed
we saw that the percentages of cells in specific phases
change after day 4, as more and more cells enter the non-
proliferating class. We find it plausible that a cell that has
entered S-phase will finish it and therefore be less prone
to entering nonproliferation. Thirdly, there is an addi-
tional time-dependent cytotoxic effect ε for both classes in
the presence of drug. We assume the log-kill hypothesis,
i.e. the cell kill is proportional to the instantaneous popu-
lation [32]. Both equations are supplied with initial matu-
rity distributions p0 and n0 at time 0.
The cytostatic action of the drug changes the maturation
velocity 1 – δ of the proliferating cells. The ordinary differ-
ential equation
describes the characteristic curves of equation (2). Since
maturation is irreversible, the function δ must satisfy 0 ≤
δ (a, t) ≤ 1. In the absence of cytostatic effects, we have δ
= 0. Then a - t = const, that is cells age one-to-one with
time, as stated earlier. On the other hand, if δ ≈ 1, cell mat-
uration is (almost) completely blocked. Observe from
equation (8) that δ is a dimensionless quantity.
da
dt
at =− 1 δ(,)
da
dt
at =− 1 δ(,)
Table 2: Cytostatic and cytotoxic effects as functions of drug dose. See equations (11) and (12) for explanations
drug concentration (d, μM) 0.1 0.5 1 2
 (d) (dimensionless) 0.3 0.6 0.77 0.92
 (d) (dimensionless) 000 0 . 8
ε0(d) (h-1)6 · 1 0 -4 1.1·10-3 1.3·10-3 1.8·10-3
δG1
δG2
A The age-dependent probability of division φ (solid blue line) and the corresponding division rate β (dashed green line) are  shown. φ is given by a shifted Γ-distribution with mean 19 h (equation (10)) Figure 6
A The age-dependent probability of division φ (solid blue line) and the corresponding division rate β (dashed green line) are 
shown. φ is given by a shifted Γ-distribution with mean 19 h (equation (10)). Observe that the units of a are hours. However, 
cytostatic effects result in a slowed progression through the cell cycle. B We show the cell-phase-dependent tendency of cells 
to become nonproliferating μ(a) (see equation (7)).
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The model predicts the total cell number (1) as well as the
percentages of cells in the three stages of the cell cycle.
(Cells in G2- and M-phases are counted together.) These
are defined as
where the boundaries between compartments   and aS
are chosen on the basis of experimental observations and
aM is the maximum age (see Table 1 and Figure 6B). More
precisely, the control scenario data were used to fix the
parameters   and  aS. We compared the fractions of cells
in each phase over time, determined by analysis of DNA
content, to the model simulation from equations (9). Fol-
lowing [33], we have chosen the distribution of intermi-
totic times φ to be a specific shifted Γ-distribution
Here am is the minimal maturity a cell has to reach before
it can divide. The parameter σ determines the standard
deviation of ϕ (see Table 1 and Figure 6A). The corre-
sponding age-dependent proliferation rate is given by
where
is the fraction of cells that reach age a without division
(see Figure 6A). We allow for a certain percentage to reach
maximum age aM without division. As argued by [34], the
mean duration of the cell cycle in solid tumors is relatively
constant and therefore not influenced by the total cell
number M.
Another source of uncertainty lies in the initial age distri-
butions p0 and q0 at time 0. The experimental data indi-
cated that initially proliferating cells in all stages of the cell
cycle were present while there were no nonproliferating
cells. It should be remarked that in the absence of nonlin-
ear crowding effects one would observe asynchronous
exponential growth. That is, the total cell number would
grow exponentially with a certain well-defined rate λ
while the percentage of cells in each age bracket would
approach a steady state. This phenomenon has been
widely studied in the population dynamics literature; we
refer here to [35] and the references therein.
How do we let the drug act on the cells? We want to test
the hypothesis that only cells in G1-phase are blocked
while cells in other phases remain unaffected. Hence, we
let
where d is the drug concentration,   (d) ≤ 1 is a dose-
dependent rate corresponding to maximum blocking
effect and T = 144 h is the duration of the experiment. We
decided to let the action increase linearly with respect to
time throughout the entire duration of the experiment.
When we tried the simplest way to model time depend-
ence, namely a sudden switch from 0 to a constant   >
0, the model predicted oscillations in the percentages that
were not present in the experimental data. At the higher
concentration of 2 μM it becomes necessary to introduce
an action of the drug on cells in G2/M-phase, similar to
equation (11). In order to explain the decrease of cell
counts from day 5 to day 6 we assume that the additional
mortality is of the type
ε(t) = max{0, ε0(d)·(t - 120)}.
We list the numerical values of the parameters that are
fixed throughout all scenarios in Table 1. The values of the
parameters   (d) and ε0(d) that differ for specific doses
are stated in Table 2. We find that the dependence of 
(d) on the drug dosage d is described very well by the
equation
with  c1  = 3.5 (Figure 3A). A similar
behavior can be surmised for the dependence of the cyto-
toxic effect ε0(d), which follows
with c2 = 4.7·10-3 and c3 = 2.1 (Figure 3B). The functional
relationships (13) and (14) are usable for any dose within
a certain range.
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